2071-P: Gastric Emptying in Youth on Glucagon-Like Peptide 1 Receptor Agonists

Introduction and Objective: Glucagon-like peptide-1 receptor agonists (GLP1) treat obesity and type 2 diabetes (T2D) by mimicking incretins, reducing appetite through delayed gastric emptying. This raises concern for retained gastric contents (GC) during sedated procedures which may increase aspiration risk. Adult studies demonstrate solid retention despite fasting, prompting a variety of recommendations to hold GLP1s before procedures. Pediatric data are lacking. We evaluated gastric emptying in youth on GLP1s, to inform preoperative management. Methods: Diabetes status, GLP1 use, and fasting duration were recorded. Point-of-care ultrasound assessed GC. Groups were compared using t-tests and Fisher’s exact tests. Multivariable logistic regression assessed associations of GLP1 use and T2D with GC. Results: Seventeen participants aged 13-21 underwent gastric ultrasound (13 on GLP1 [7 with T2D, 6 without]; 4 not on GLP1 [1 with T2D, 3 without]). Characteristics/findings are summarized in Table 1. In multivariable logistic regression, GLP1 use was not significantly associated with the presence of GC (OR 1.33, 95% CI 0.10-17.10, p=0.83). When adjusted for GLP1 use, T2D status was also not significantly associated with presence of GC (OR 0.61, 95% CI 0.07-5.4, p=0.66). Conclusion: GLP1 use was associated with higher but non-significant odds of GC, with no difference by T2D status. More participants are needed to clarify the impact of GLP1 use on gastric emptying in pediatric preoperative care. Disclosure N. Segev: None. I.G. Allen: None. N. Yayah Jones: Consultant; Current; Medtronic, Sanofi. A. Shah: Consultant; Ended; AbbVie Inc. S. Narayanasamy: None.